Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22330419 | 1.00 | EGFR (0.32) | EGFR | |
| SCHEMBL24464699 | 0.77 | KDM4E (0.37) | EGFR | |
| SCHEMBL20629281 | 0.75 | — | — | |
| SCHEMBL22488049 | 0.74 | — | — | |
| SCHEMBL19954662 | 0.73 | MEN1 (0.33) | EGFR | |
| SCHEMBL21888673 | 0.73 | — | — | |
| SCHEMBL13124171 | 0.73 | EGFR (0.44) | EGFR | |
| SCHEMBL19432683 | 0.71 | — | — | |
| SCHEMBL23768160 | 0.71 | MEN1 (0.32) | EGFR | |
| SCHEMBL18610516 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006035-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Neupharma, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | IDH1, IDH2, IDH3A | EGFR 1883/4885 |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | EGFR 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.